X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
AJANTA PHARMA Fact Sheet, AJANTA PHARMA Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA Fact Sheet   (AJPH)

Here is the latest financial fact sheet of AJANTA PHARMA. For more details, see the AJANTA PHARMA quarterly results and AJANTA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.

AJANTA PHARMA Price History

Price Rs 1,512.4
Mkt Cap Rs m 133,016
Vol '000 7.0
P/E X 26.2
P/CF X 29.8
EPS (TTM) Rs 57.6
% ch % -0.8
No. of shares m 87.95
% ch week % -2.6
% ch 1-mth % -9.5
% ch 12-mth % 4.5
52 week H/L Rs 2,150.0/1,400.1
(As on Jun 23, 2017 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

AJANTA PHARMA Financials

No. of Mths
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
AJANTA PHARMA EQUITY SHARE DATA
High Rs4926981,1777791,720 
Low Rs2012316252991,103 
Sales per share (Unadj.) Rs571.2392.4340.8166.1194.6 
Earnings per share (Unadj.) Rs65.247.366.034.945.2 
Diluted earnings per shareRs8.812.726.635.245.6 
Cash flow per share (Unadj.) Rs92.061.778.340.850.3 
Dividends per share (Unadj.) Rs7.506.2510.006.008.00 
Adj. dividends per shareRs1.011.694.036.058.07 
Dividend yield (eoy) %2.21.31.11.10.6 
Book value per share (Unadj.) Rs251.3165.9167.394.8132.0 
Adj. book value per shareRs33.944.767.595.6133.3 
Shares outstanding (eoy) m11.8623.7235.4688.7188.77 
Bonus/Rights/Conversions  -FV5B1:2,ESOSFV2- 
Price / Sales ratio x0.61.22.63.27.3 
Avg P/E ratio x5.39.813.715.431.2 
P/CF ratio (eoy) x3.87.511.513.228.1 
Price / Book Value ratio x1.42.85.45.710.7 
Dividend payout %11.513.215.217.217.7 
Avg Mkt Cap Rs m4,10911,02131,95147,797125,299 
No. of employees `000NANANANANA 
Total wages/salary Rs m9381,2321,5702,0062,570 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
AJANTA PHARMA INCOME DATA
Net Sales Rs m6,7749,30812,08314,73617,275 
Other income Rs m6256137168166 
Total revenues Rs m6,8369,36412,22114,90417,442 
Gross profit Rs m1,3202,2453,6885,0525,807 
Depreciation Rs m319342439516451 
Interest Rs m154191875949 
Profit before tax Rs m9101,7683,2994,6455,474 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m000-850 
Tax Rs m1376479601,4621,460 
Profit after tax Rs m7731,1212,3393,0994,014 
Gross profit margin %19.524.130.534.333.6 
Effective tax rate %15.136.629.131.526.7 
Net profit margin %11.412.019.421.023.2 
AJANTA PHARMA BALANCE SHEET DATA
Current assets Rs m3,3973,6905,2016,3347,639 
Current liabilities Rs m2,5022,2232,7542,4962,715 
Net working cap to sales %13.215.820.226.028.5 
Current ratio x1.41.71.92.52.8 
Inventory Days Days9058473943 
Debtors Days Days7659616479 
Net fixed assets Rs m2,4862,8513,7294,5836,914 
Share capital Rs m118118177177177 
"Free" reserves Rs m2,8253,7745,6508,18611,442 
Net worth Rs m2,9803,9345,9338,41111,721 
Long term debt Rs m761733523333149 
Total assets Rs m6,4887,1829,49411,46414,814 
Interest coverage x6.910.238.879.5112.9 
Debt to equity ratio x0.30.20.100 
Sales to assets ratio x1.01.31.31.31.2 
Return on assets %14.318.325.627.527.4 
Return on equity %25.928.539.436.834.2 
Return on capital %28.442.052.452.846.5 
Exports to sales %50.654.454.754.755.1 
Imports to sales %5.65.65.04.46.0 
Exports (fob) Rs m3,4275,0676,6068,0629,527 
Imports (cif) Rs m3775246026531,038 
Fx inflow Rs m3,5485,3336,8968,49410,422 
Fx outflow Rs m6809351,1681,2471,678 
Net fx Rs m2,8684,3995,7287,2478,744 
AJANTA PHARMA CASH FLOW
From Operations Rs m 704 2,343 2,124 2,794 3,264 
From Investments Rs m -531 -1,037 -1,878 -1,584 -2,093 
From Financial Activity Rs m -128 -1,045 -201 -1,052 -1,186 
Net Cashflow Rs m 44 261 45 159 -15 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 73.8%
Foreign collaborators 0.0%
Indian inst/Mut Fund 1.6%
FIIs 7.6%
ADR/GDR 0.0%
Free float 17.0%
Shareholders 20,968
Pledged promoter(s) holding 4.4%
 

Company Information

REGD OFF Ajanta House, Charkop, Kandivli (W), Mumbai - 400 067
E-MAIL deodatta.pandit@ajantapharma.com WEB www.ajantapharma.com
TELEPHONE (022) 66061000 FAX (022) 6606 1200
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
AUDITOR Kapoor & Parekh Assoc.
CHM: Mannalal B. Agrawal COMP SEC: Gaurang Shah YEAR OF INC: 1979 BSE CODE: 532331 FV (Rs): 5 DIV YIELD (%): 0.5

More Pharmaceuticals Company Fact Sheets:   MERCK LTD  INDRAPRASTHA MEDICAL  DISHMAN PHARMA  PANACEA BIOTECH  INDOCO REMEDIES  

Compare AJANTA PHARMA With:   MERCK LTD  INDRAPRASTHA MEDICAL  DISHMAN PHARMA  PANACEA BIOTECH  INDOCO REMEDIES  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Share Markets End the Week on a Dull Note(RoundUp)

Global financial markets ended the week on a dull note. This was on back of the Federal Reserve's release of its May 2-3 policy meeting minutes.

Views on news

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

More Views on News

Most Popular

A Pharma IPO in a Market That Loves IPOs but Hates Pharma(The 5 Minute Wrapup)

Jun 15, 2017

Tomorrow comes the IPO of Eris Lifesciences. How will a pharma IPO do in this market?

Bitcoin at $10,000?(Vivek Kaul's Diary)

Jun 14, 2017

Whether you're Venezuela or China or in India or the US...and you want to protect your wealth, you need real money. All the government has on offer is funny money.

Get Ready for Commodity Options!(Daily Profit Hunter)

Jun 16, 2017

Commodity options trading is one step closer to reality. Learn how to take advantage of this tremendous opportunity.

Walter Schloss' Investing Record(Chart Of The Day)

Jun 17, 2017

In a market full of one-hit-wonders, this investor obviously had a formula that worked. And through the think-and-thin of the market.

11 Hidden Costs Associated With Your Home Loan(Outside View)

Jun 16, 2017

Various costs associated with a home loan.

More

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AJANTA PHARMA

AJANTA PHARMA - TEVA PHARMA COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS